TrialThe Journal of infectious diseases2013

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Papa Salif Sow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.